KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Adaptive Biotechnologies (ADPT) Net Margin (2018 - 2025)

Adaptive Biotechnologies' Net Margin history spans 8 years, with the latest figure at 17.82% for Q4 2025.

  • For Q4 2025, Net Margin rose 5323.0% year-over-year to 17.82%; the TTM value through Dec 2025 reached 20.91%, up 6827.0%, while the annual FY2025 figure was 21.47%, 6771.0% up from the prior year.
  • Net Margin for Q4 2025 was 17.82% at Adaptive Biotechnologies, down from 10.95% in the prior quarter.
  • Across five years, Net Margin topped out at 10.95% in Q3 2025 and bottomed at 620.92% in Q2 2023.
  • The 5-year median for Net Margin is 110.3% (2024), against an average of 125.35%.
  • The largest annual shift saw Net Margin tumbled -50163bps in 2023 before it skyrocketed 51384bps in 2024.
  • A 5-year view of Net Margin shows it stood at 161.76% in 2021, then soared by 59bps to 66.28% in 2022, then tumbled by -129bps to 151.73% in 2023, then skyrocketed by 53bps to 71.04% in 2024, then surged by 75bps to 17.82% in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Net Margin are 17.82% (Q4 2025), 10.95% (Q3 2025), and 43.47% (Q2 2025).